Jefferies rates Accentia at buy

Accentia Biopharmaceuticals Inc. was rated at a buy by Jefferies & Co., Inc. analyst Adam Walsh. The analyst believes the start of SinuNase phase 3 trials will serve as a catalyst to drive the company's shares higher and that management will continue to control balance sheet pressures. Accentia reported second-quarter GAAP loss per share of $0.40, compared to Jefferies' $0.32 loss per share estimate. Shares of the Tampa, Fla., pharmaceutical company were down 14 cents, or 4.56%, at $2.93 on volume of 19,232 shares versus the three-month running average of 30,132 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.